Treats Parkinson’s disease (PD). ANDA 201942, held by Carnegie. Rasagiline Mesylate.
As of Nov 21, 2026, ANDA 201942 (Rasagiline Mesylate), held by Carnegie, was first approved by FDA on Nov 18, 2021, with 0 approved supplements and 0 published complete response letters.
Rasagiline tablets are indicated for the treatment of Parkinson’s disease (PD).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 18, 2021 | Original application | Approved | None posted |
| Rasagiline MesylateEQ 0.5MG BASE · tablet;oral | Rasagiline Mesylate | Rx |
| Rasagiline MesylateEQ 1MG BASE · tablet;oral | Rasagiline Mesylate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters